Sitagliptin 100 mg tablets,Januvia 100 mg tablets
Sponsors
Bio-innova and Synchron.Co.,Ltd, Bio-innova Co., Ltd.
Conditions
Healthy subjects
Bioequivalence Sitagliptin 100 mg tabletsHealthy subjects
Sitagliptin
BioequivalenceHealthy subjects
Sitagliptin
bioequivalenceHealthy volunteers, A Bioequivalence safety study
Bioequivalence Sitagliptin 100 mg tablets
Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin 100 mg tablets relative to Januvia 100 mg tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20210217006
Start: 2021-05-25Target: 26Updated: 2026-08-03
A randomized, open-label, single dose, two-way crossover bioequivalence study of Sitagliptin 100 mg Tablets relative to Januvia (Sitagliptin) 100 mg Tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20210406003
Start: 2021-07-13Target: 40Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin 100 mg Tablets relative to Januvia (Sitagliptin) 100 mg Tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20210518003
Start: 2021-07-05Target: 40Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin 100 mg tablets relative to Januvia 100 mg tablets in healthy Thai volunteers under fasting condition
TCTR20230811011
Start: 2023-09-12Target: 26Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin 100 mg tablets relative to Januvia 100 mg tablets in healthy Thai participants under fasting condition.
Active, not recruitingTCTR20251124001
Start: 2026-03-03Target: 26Updated: 2026-08-03